Compare Quest Diagnostics Inc (DGX) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs S&P500 ETF — how do they compare? Quest Diagnostics Inc trades at $204.68 (market cap $22.80B), while S&P500 ETF trades at $754.74. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, Quest Diagnostics Inc nearer its low. Which is the better fit depends on your goals.
| DGX | SPY | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | — |
52-Week High | $216.02 | $759.55 |
52-Week Low | $166.42 | $621.75 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SPY trades at $749.08, down 0.77% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF approaches key resistance at $750 with support at $747. Recent news highlights analyst optimism with several firms projecting S&P 500 targets above 8,000 by year-end, though earnings season and inflation data remain key catalysts.
Outlook remains constructive given strong institutional sentiment and historical market performance, though risks include potential Fed policy shifts and valuation concerns. The dividend payment scheduled for July 31, 2026 provides income support, while technical consolidation near all-time highs suggests potential for breakout momentum if earnings deliver.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
